Yıl: 2013 Cilt: 44 Sayı: 4 Sayfa Aralığı: 190 - 196 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Kanser Kök Hücresi

Öz:
Kök hücrelerin sağlıklı organizma ve hastalıklar üzerindeki rolü son yıllarda yapılan çalışmalarda önemli gelişmelere neden olmuştur. Kanser dokusunda, patogenezden sorumlu tutulan artmış büyüme potansiyeline sahip, uzun ömürlü hücre popülasyonu kanser kök hücreleri (KKH) olarak adlandırılırlar. KKHlerinin kemoterapiye dirençli, saldırgan ve tekrarlayan tümörlerden sorumlu olduğu düşünülmektedir. Klinik tıpta hücre biyolojisine dair bildirimler artmıştır, özellikle tümör metastazı ile gelişmelerde önemli bir rol oynamaktadır. Kanser kök hücreleri tümör metastazında önemli bir role sahip olabilir ve prognostik belirleyiciler anlaşıldığı takdirde gelecekte yapılacak çalışmalar kanserin tedavisi için KKHlerini hedef alan tedavilerin geliştirilmesine öncülük edecektir.
Anahtar Kelime:

Konular: Hematoloji Onkoloji Hücre Biyolojisi

Cancer Stem Cell

Öz:
There has been a growing important in recent years in the role stem cells play in health and disease. In the cancer tissue, this population of long lived cells with extraordinary expansion potential has been called tumor initialing cells or cancer stem cells (CSCs). It ıs thought that CSCs are responsible for these aggressive and reccurent tumors.Research has been increasing in recent years into the application of stem cell biology to clinical medicine, particularly it s role in the evolution and metastasis tumours.Cancer stem cell may have a specific role in tumour metastasis, and their understanding may provide insight into the development of predictive and prognostic markers, future studies shoul lead to development of CSCs targeted therapies for cancer treatment.
Anahtar Kelime:

Konular: Hematoloji Onkoloji Hücre Biyolojisi
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1.Tuna M. Solid tümörlerde ve lösemilerde kanser kök hücresi. Türk Onkoloji Dergisi 2009; 24(1): 42-47.
  • 2.Amabile G, Meissner A. Induced pluripotent stem cells:current progress and potential for regenerative medicine. Trends Mol.Med. 2009;15:58-68.
  • 3.Bapat S. Cancer stem cells. Indentification and Targets. 2009 Wiley&Sons Inc.USA.
  • 4. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998 Nov 6; 282 (5391):1145-1147.
  • 5. Kakarala M, Wicha MS. Cancer stem cells: İmplications for cancer treatment and prevention. Cancer J 2007;13(5):271-5.
  • 6. Draper JS, Fox V. Human embriyonic stem cells: Multilineage differentiation and mechanisms of selfrenewal. Arc. Med. Res. 2003; 34:558-564.
  • 7. Trounson A. The production and directed differentiation of human embryonic stem cells. Endocr Rev. 2006; 27(2): 208-219.
  • 8. Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, Ding S. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci U S A. 2006; 103(18) : 6907-6912.
  • 9. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005; 280(26): 24731-24737.
  • 10. Ivanova NB, Dimos JT, Schaniel C, Hakney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science. 2002; 298: 601-4.
  • 11. Demiray ŞB, Ayla Ş, Oltulu F, Çavuşoğ- lu T, Akarca Ö, Dilsiz ÖY, Ergüven M, Öktem G, Bilir A. MDAH-2774 Over kanser kök hücrelerinde kemoterapi sonrası apoptotik etkilerin incelenmesi. Ege Tıp Dergisi. 2011; 50(2):103-109.
  • 12.. Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, et al. Tumour-initiating cells vs cancer “stem” cells and CD133: what’s in the name? Biochem Biophys Res Commun 2007;355:855–9.
  • 13. Cory S and Adams, J. M. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002; 2: 647–56.
  • 14. Schuler M and Green D R. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans . 2001: 29; 684–8.
  • 15. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23(43):7274-82.
  • 16. Fei R, Wei QS, Xiang D. CD133 A cacer stem cells marker, is used in colorectal cancers. World J. Gastroenterology . 2013.7 9(17):2603-2611.
  • 17. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-9344.
  • 18. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. Breast cancer res. 2008;10(2):105.
  • 19.Spillane JB, Handerson AM. Canser stem cells: A revıew. ANZ J surg. 2007; 77:464- 468.
  • 20. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002; 3:508-13.
  • 21. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat.Rev. 2003;3:895-902.
  • 22.Dontu G, Al-Hajj M, Abdullah W, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003; 36 (Suppl.1):59-72.
  • 23.Tanır HG, Demirezen Ş. Wnt sinyal yolunun biyolojisi ve bu yolda görev alan biyomoleküller. Turkiye Klinikleri J Med Sci 2009;29(5):1292-7.
  • 24. 86. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A, Armas A. Betacatenin expression pattern in stage I and II ovarian carcinomas: relationship with betacatenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-536.
  • 25. Akisik E, Buğra D, Yamaner S, Dalay N. Analysis of β- catenin alterations in colon tumors: a novel exon 3 mutation. Tumour Biol 2011;32:71-76.
  • 26. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Wicha MS. Role of Notch signalling in cell-fate determination of human mammary stem/progenitor cells. Breast cancer resc.2004; 6:605-615.
  • 27. WA Schulz. Molecular Biology of Human Cancers. The Netherlands: Springer 2007.
  • 28. Weber GF. Molecular Mechanisms of Cancer. The Netherlands: Springer 2007.
  • 29. Krauss G. Biochemistry of signal transduction and regulation 3rd ed. Wiley-VCH 2003.
  • 30. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007;11(5):981- 1011.
  • 31. Wu XZ. Origin of cancer stem cells: the role of selfrenewal and differentiation. Ann Surg Oncol. 2008;15(2):407-14.
APA AYLA Ş, Öktem G, TANRIVERDİ G, BİLİR A (2013). Kanser Kök Hücresi. , 190 - 196.
Chicago AYLA ŞULE,Öktem Gülperi,TANRIVERDİ GAMZE,BİLİR Ayhan Kanser Kök Hücresi. (2013): 190 - 196.
MLA AYLA ŞULE,Öktem Gülperi,TANRIVERDİ GAMZE,BİLİR Ayhan Kanser Kök Hücresi. , 2013, ss.190 - 196.
AMA AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A Kanser Kök Hücresi. . 2013; 190 - 196.
Vancouver AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A Kanser Kök Hücresi. . 2013; 190 - 196.
IEEE AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A "Kanser Kök Hücresi." , ss.190 - 196, 2013.
ISNAD AYLA, ŞULE vd. "Kanser Kök Hücresi". (2013), 190-196.
APA AYLA Ş, Öktem G, TANRIVERDİ G, BİLİR A (2013). Kanser Kök Hücresi. Zeynep Kamil Tıp Bülteni, 44(4), 190 - 196.
Chicago AYLA ŞULE,Öktem Gülperi,TANRIVERDİ GAMZE,BİLİR Ayhan Kanser Kök Hücresi. Zeynep Kamil Tıp Bülteni 44, no.4 (2013): 190 - 196.
MLA AYLA ŞULE,Öktem Gülperi,TANRIVERDİ GAMZE,BİLİR Ayhan Kanser Kök Hücresi. Zeynep Kamil Tıp Bülteni, vol.44, no.4, 2013, ss.190 - 196.
AMA AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A Kanser Kök Hücresi. Zeynep Kamil Tıp Bülteni. 2013; 44(4): 190 - 196.
Vancouver AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A Kanser Kök Hücresi. Zeynep Kamil Tıp Bülteni. 2013; 44(4): 190 - 196.
IEEE AYLA Ş,Öktem G,TANRIVERDİ G,BİLİR A "Kanser Kök Hücresi." Zeynep Kamil Tıp Bülteni, 44, ss.190 - 196, 2013.
ISNAD AYLA, ŞULE vd. "Kanser Kök Hücresi". Zeynep Kamil Tıp Bülteni 44/4 (2013), 190-196.